UK drugmaker GSK said its asthma drug Nucala has achieved the primary endpoint of a late-stage study in patients with chronic obstructive pulmonary disease, or smoker’s lung. According to GSK, patients treated with Nucala and maintenance inhaled therapy for 104 weeks had a lower average annual rate of moderate to severe exacerbations than those taking a placebo.